A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Daunorubicin liposomal (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics; Proof of concept
- 10 Jun 2017 Biomarkers information updated
- 04 Nov 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
- 04 Nov 2016 Status changed from not yet recruiting to recruiting.